May 05, 2022 / 11:00AM GMT
Jonas Jarvius - Q-linea AB - CEO
Thank you very much for that introduction. And welcome, everyone, to our presentation for the first-quarter of 2022. I think we start with moving to the next slide, showing our disclaimer slide in case we are on this. We'll make any forward-looking statements as you have here on slide number 2.
With that, I think we move into the activities for the first quarter on slide number 3. So of course, you who follow us know that Q-linea is working with developing disruptive solutions for faster infectious disease diagnostics. We have a product on the market. We'll talk about that today. It's ASTar, and it's targeting bloodstream infections, where sepsis is the most severe of these syndromes.
We are based in Uppsala, Sweden. We have three sites, active sites with covering R&D, of course, commercial activities but also production because we focused on production on our consumables. And you can see that on the right of your screen, where you see ASTar being the instrument platform and then the various kits for different type of applications.
So to
Q1 2022 Q linea AB Earnings Call Transcript
May 05, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers